Larnamin 3g / 5g 30s granules sachets for oral solution

The instruction for medical use of LARNAMIN medicine the Trade name Larnamin Mezhdunarodnoye the unlicensed name Is not present the Dosage form of the Granule for preparation of oral solution, 3 g / 5 Structure of 1 sachet active agent - L-ornithine L-contains aspartate in terms of 100% substance - 3 g excipients: anhydrous citric acid, fragrance orange, fragrance a lemon, saccharin of sodium, sodium cyclomate, a yellow decline of FCF (E 110), povidone, maltit (E 965). Description Mix of granules of the different extent of white and orange colors. Pharmacotherapeutic group Drugs for treatment of diseases of a liver and biliary tract. Drugs for treatment of diseases of a liver. The ATX A05BA code the Pharmacological Pharmacokinetics Not properties it was investigated. In vivo pharmacodynamics effect of L-ornithine of L-aspartate is caused by amino acids, ornithine and aspartate, is carried out by means of two key methods of a detoxication of ammonia: synthesis of urea and synthesis of a glutamine. Synthesis of urea happens in periportal hepatocytes where ornithine acts as the activator of two enzymes: ornithine of a karbamoiltransferaza and the karbamoilfosfat of a sintetaza and also as substrate for urea synthesis. Synthesis of a glutamine happens in perivenous hepatocytes. In particular, under pathological conditions, aspartate and dicarboxylate, including ornithine metabolism products, are absorbed in cells and used for binding of ammonia in the form of a glutamine there. The glutamate is an amino acid which connects ammonia as under physiological, and pathological conditions. The received amino acid represents a glutamine not only a non-toxic form for ammonia removal, but also activates intracellular exchange of a glutamine. Under physiological conditions ornithine and aspartate do not limit urea synthesis. Pilot studies on animals showed that the ability of L-ornithine of L-aspartate to reduce the level of ammonia is caused by the accelerated synthesis of a glutamine. In separate clinical trials this improvement in the relation of a branched chain of amino acids / aromatic amino acids was shown. L-aspartate L-ornithine it is quickly absorbed and split on ornithine and aspartate. Elimination half-life of both amino acids short – 0.3-0.4 hours. A part of aspartate is removed with urine in not changed look. Indications - the acute and chronic diseases of a liver accompanied with a giperammoniyemiya (including cirrhoses, a viral hepatitis, in fat dystrophy, toxic damages of a liver against the background of an alcoholic poisoning) - hepatic encephalopathy (latent and expressed) the Route of administration and doses Contents of 1-2 sachets of Larnamina® to dissolve and accept up to 3 times a day. To dissolve a sachet of Larnamina® in a large amount of liquid (for example in a glass of water or juice) and to accept in time or after meal. Duration of treatment is determined by the doctor depending on a clinical condition of the patient. Side effects Sometimes (≥1/1000, & lt, 1/100) - allergic symptoms in the form of the complicated breath (asthma attacks) and skin rashes - nausea, vomiting, a stomach ache, a meteorism, diarrhea Very seldom (≥1/10) - a joint pain These side reactions usually short-term also do not demand the termination of administration of drug. Contraindications – the hypersensitivity to L-ornithine to L-aspartate or to any of excipients – heavy renal failures (chronic or acute renal failure) at the level of creatinine is higher than 3 mg / 100 of ml – children's and teenage age up to 18 years. Medicinal interactions of the Research on interaction were not carried out. Data are absent. The special instructions Use in pediatrics the Experience of use to children is limited therefore drug should not be used in pediatric practice. Use during pregnancy and a lactation the Data on Larnamin's use during pregnancy are absent. Researches on animals using L-aspartate L-ornithine for studying its toxic influence on reproductive function were not conducted. Thus, Larnamin's use during pregnancy should be avoided. It is unknown whether gets L-aspartate L-ornithine into breast milk. Therefore it is necessary to avoid use of drug during feeding by a breast. Features of influence of drug on ability to run transport and potentially dangerous mechanisms Owing to a disease the ability to run motor transport or work with other mechanisms can be worsened during treatment by L-ornithine L-aspartate therefore it is necessary to avoid such type of activity during treatment. Overdose Today the symptoms of intoxication caused by L-ornithine overdose by L-aspartate were not observed. Symptoms: strengthening of side effects. Treatment: symptomatic treatment. A form of release and packing On 5 g of granules for preparation of oral solution in a sachet from a folgoplen. On 30 sachets together with the instruction for medical use in the state and Russian languages put in a pack from cardboard. To Store storage conditions at a temperature not above 25 °C. To store out of children's reach! A period of storage 2 years not to use drug after the expiration date specified on packing. Prescription status Without prescription. PJSC Pharmak producer, Ukraine, 04080, Kiev, st. of Frunze, 74. The holder of the registration certificate of PJSC Pharmak, Ukraine the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) and responsible for post-registration observation of safety of medicine Representative office of PJSC Pharmak in the Republic of Kazakhstan the Republic of Kazakhstan, Almaty, index 050012, Amangelda St. 59 'A' Business center 'Shartas', the 9th floor.